Annals of Surgical Oncology

, Volume 26, Issue 5, pp 1236–1237 | Cite as

ASO Author Reflections: Oncotype DX RS Complementing the Prognostic Stage in the Updated AJCC 8th Edition for T1-2N1M0 ER-Positive HER2-Negative Breast Cancer

  • Maoli Wang
  • Kejin Wu
  • Hongliang ChenEmail author
ASO Author Reflections



Authors declare that he has no conflicts of interest.


  1. 1.
    Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol. 2018;25:1783–5.CrossRefGoogle Scholar
  2. 2.
    Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65.CrossRefGoogle Scholar
  3. 3.
    Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28:1829–34.CrossRefGoogle Scholar
  4. 4.
    Gluz O, Nitz UA, Christgen M, et al. West German Study Group phase 3 plan B trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 2016;34:2341–9.CrossRefGoogle Scholar
  5. 5.
    Wang M, Wu K, Zhang P, et al. The prognostic significance of Oncotype DX recurrence score in T1-2N1M0 ER-positive HER2-negative breast cancer based on the prognostic stage in the updated AJCC 8th edition. Ann Surg Oncol. 2018.

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of Breast SurgeryObstetrics and Gynecology Hospital of Fudan UniversityShanghaiChina

Personalised recommendations